Utility of Molecular Testing for Identifying Targetable Molecular Alterations and Supporting a Diagnosis of Anaplastic Thyroid Carcinoma on Core Needle Biopsy
International Journal of Surgical Pathology · 13.11.2026
DOI: 10.1177/10668969261493450 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Surgical Pathology, online erschienen am 13.11.2026. Verfasst von Matthew Leong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cedars-Sinai Medical Center.
Abstract (Originalsprache)
Background
Molecular testing of anaplastic thyroid carcinoma (ATC) is recommended by the American Thyroid Association early in diagnosis to support a diagnosis of ATC in specimens of ambiguous morphology/immunophenotype and enable possible alternative systemic treatment options. Ideally, molecular testing should be performed on the initial diagnostic pathology sample, frequently the core needle biopsy (CNB) specimen, despite potential concerns about tissue sufficiency. This study aimed to determine the practical feasibility and treatment implications of performing molecular testing, primarily in-house next-generation sequencing (NGS), on CNB with ATC.
Methods
This study was a retrospective review of CNB performed within our institution in which a diagnosis of ATC was considered. Molecular and immunohistochemistry (IHC) results were reviewed and, if not initially ordered, performed on available tissue.
Results
In a cohort of 24 specimens, molecular testing was successfully performed on all specimens; however, tissue scarcity limited molecular and IHC analysis for 5 specimens. Mutations in ATC-associated genes were identified in all specimens, including BRAF p.V600E (58%), RAS family (21%), and TP53 (38%). NGS testing also enabled the evaluation of microsatellite instability (MSI; 0% high), tumor mutational burden (TMB; 9% high), and a number of other potential biomarkers. Although BRAF V600E IHC demonstrated 100% sensitivity and specificity after blinded expert retrospective review, 20% of initial IHC interpretations were incorrectly or ambiguously categorized, highlighting the significant inter-observer variability associated with BRAF IHC interpretation.
Conclusion
Molecular testing on CNB is feasible and provides broader biomarker coverage with greater consistency and less interpretative variability than IHC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
ORCID-Profile: Matthew Leong, Cedric Bailey, Allen Ho, Bonnie Balzer, Matthew Gayhart, Eric Vail, Xuemo Fan
Förderung
- Cedars-Sinai Medical Center
Zitieren
APA
Leong, M., Bailey, C., Kniola, W., Ho, A., Balzer, B., Gayhart, M., Vail, E., & Fan, X. (2026). Utility of Molecular Testing for Identifying Targetable Molecular Alterations and Supporting a Diagnosis of Anaplastic Thyroid Carcinoma on Core Needle Biopsy. International Journal of Surgical Pathology. https://doi.org/10.1177/10668969261493450
Vancouver
Leong M, Bailey C, Kniola W, Ho A, Balzer B, Gayhart M, et al. Utility of Molecular Testing for Identifying Targetable Molecular Alterations and Supporting a Diagnosis of Anaplastic Thyroid Carcinoma on Core Needle Biopsy. International Journal of Surgical Pathology. 2026. doi:10.1177/10668969261493450
BibTeX
@article{Leong2026,
author = {Leong, Matthew and Bailey, Cedric and Kniola, Wyleen and Ho, Allen and Balzer, Bonnie and Gayhart, Matthew and Vail, Eric and Fan, Xuemo},
title = {Utility of Molecular Testing for Identifying Targetable Molecular Alterations and Supporting a Diagnosis of Anaplastic Thyroid Carcinoma on Core Needle Biopsy},
journal = {International Journal of Surgical Pathology},
year = {2026},
doi = {10.1177/10668969261493450}
}
EUVIMED